human : 48
mouse : 1
|Mouse||CDKN2C||1031||cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)|
Mice lacking both p18 and p53 develop several tumors not reported in either single null genotype, including hepatocellular carcinoma, testicular choriocarcinoma, hemangiosarcoma, leiomyosarcoma, fibrosarcoma, and osteosarcoma.
up-regulation of miR-221 expression is an accurate way to differentiate leiomyosarcoma from benign metastasizing leiomyoma
|Human||PRUNE2||158471||prune homolog 2 (Drosophila)|
OBSCN and C9orf65 comprise a highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas
|Human||FBLIM1||54751||filamin binding LIM protein 1|
Results suggest a role for cytoplasmic migfilin in the progression of leiomyosarcomas (LMS) and identify cytoplasmic migfilin as a potentially important biological marker for human LMS progression
|Human||RRAS2||22800||related RAS viral (r-ras) oncogene homolog 2|
A novel insertional mutation in the TC21 gene activates its transforming activity in a human leiomyosarcoma cell line.
TC21 is a ras family member that shares close homology to H-, K- and N-ras, and activating mutations have been found in ovarian carcinoma and leiomyosarcoma cell lines.
|Human||FERMT2||10979||fermitin family member 2|
Direct sequencing of the whole coding region of mig-2 cDNA and Southern blotting revealed that mig-2 alterations, such as mutations, rearrangement, and amplification, were not present in either leiomyomas or leiomyosarcomas.
Expression of the mitogen-inducible gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas.
In contrast, the mig-2 expression was greatly decreased in leiomyosarcomas.
Among 17 mesenchymal tumors (seven leiomyosarcomas, five malignant peripheral nerve sheath tumors, and five fibrosarcomas) that occurred in sites other than the gastrointestinal tract, only two malignant peripheral nerve sheath tumors were moderately immunoreactive for nestin.
|Human||MVP||9961||major vault protein|
LRP was expressed at high levels in SPA but to a lesser extent in the other leiomyosarcomas.
In seven sarcomas of the pulmonary artery (SPA) and ten leiomyosarcomas of other origin, we studied the immunohistochemical expression of P-glycoprotein (P-gp), multidrug-resistance protein (MRP), lung resistance protein (LRP), metallothionein (MT) and topoisomerase IIalpha.
High-level expression of CD163 is associated with leiomyosarcomas
|Human||AOC3||8639||amine oxidase, copper containing 3|
In tumors, VAP-1 is retained on all leiomyoma cells, whereas it is lost in half of leiomyosarcoma samples.
|Human||HMGA2||8091||high mobility group AT-hook 2|
HMGIC gene expressions were detected in both uterine (73.3%) and extrauterine (57.1%) smooth muscle tumors by reverse transcriptase polymerase chain reaction (RT-PCR), and benign tumors (70.5%) more frequently expressed the HMGIC than leiomyo-sarcomas (57.8%).
Southern blot analysis identified a rearranged HMGIC in one soft tissue leiomyosarcoma.
We investigated molecular and genetic alterations of the HMGIC in 36 benign and malignant smooth muscle tumors arising at various anatomical sites, including 13 uterine leiomyomas, two leiomyomas of the kidney with a t(12;14), one pelvic lipoleiomyoma, one vascular leiomyoma of the foot, two uterine leiomyosarcomas, six retroperitoneal leiomyosarcomas, one leiomyosarcoma of the urinary bladder, and 10 leiomyosarcomas of external soft tissues.
Variant transcripts of the HMGIC containing cryptic exonic sequences previously described were found in one renal and three uterine leiomyomas and four leiomyosarcomas arising in the uterus and soft tissues by RT-PCR.
These results suggest that the monoclonal antibodies against vinculin and calponin may serve as additional diagnostic markers for myogenic differentiation in leiomyosarcomas and related tumors.
Since vinculin immunoreactivity could also be demonstrated in cases of leiomyosarcoma, the positive immunohistochemical detection of vinculin was not exclusively restricted to mesenchymal tumors derived from sarcomeric muscle tissue.
|Human||TIMP3||7078||TIMP metallopeptidase inhibitor 3|
Ectopic overexpression of TIMP-3 in cultured leiomyosarcoma cells conferred an epithelial morphology, reduced cell growth rate, anchorage-independent growth, and matrix invasion in vitro.
The clinical, histopathological, immunochemical, and immunocytochemical features of leiomyomas (LM) and leiomyosarcomas (LMS) were investigated by a panel of monoclonal antibodies specific for some differentiation markers of SM tissue (SM myosin and alpha-actin, desmin, and SM22) and for markers of non-muscle tissue (vimentin and non-muscle myosin).
|Human||STAT3||6774||signal transducer and activator of transcription 3 (acute-phase response factor)|
To address whether Stat3 is required for HGF/SF-Met mediated tumorigenesis and metastasis, we introduced a dominant-negative form of Stat3, Stat3beta into the human leiomyosarcoma cell line SK-LMS-1.
|Human||SSX2||6757||synovial sarcoma, X breakpoint 2|
For defined tumor types, expression of at least one of the SSX family members was most frequently observed in head and neck cancer (75%), followed by ovarian cancer (50%), malignant melanoma (43%), lymphoma (36%), colorectal cancer (27%) and breast cancer (23%), while leukemias and the few cases of leiomyosarcomas, seminomas and thyroid cancers were found not to express any SSX gene.
|Human||SNAI2||6591||snail family zinc finger 2|
SNAI2 mRNA was expressed in placenta, melanocyte, embryonic stem (ES) cells, leiomyosarcoma, neuroblastoma, and glioblastoma.
CDK4, MDM2, SAS and GLI genes are amplified in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma
|Human||PLAG1||5324||pleiomorphic adenoma gene 1|
PLAG1 over-expression was also found in three of nine mesenchymal tumors, i.e., in two uterine leiomyomas and one leiomyosarcoma.
|Human||ABCB1||5243||ATP-binding cassette, sub-family B (MDR/TAP), member 1|
Detection of P-glycoprotein and metallothionein seems to add certain prognostic value in gastrointestinal stromal neoplasms (MT) or gastrointestinal leiomyosarcomas (P-GP)
|Human||PCP4||5121||Purkinje cell protein 4|
To clarify the role of PEP-19 in the pathogenesis of leiomyomas, PEP-19 expression was investigated for a series of human leiomyoma, as well as normal myometrium and leiomyosarcoma.
|Human||NME1||4830||NME/NM23 nucleoside diphosphate kinase 1|
RESULT: The expression of nm23 declined significantly according to the following order: leiomyomas, low malignant leiomyosarcomas, high malignant leiomyosarcomas (P < 0.01).
Loss of NM-23, a reported tumor metastasis suppressor gene, was found only in leiomyosarcomas (5 of 9, or 56%), and 4 of 5 (80%) of these were the only cases that demonstrated distant metastases (P = 0.04).
RESULT: The expression of nm23 declined significantly according to the following order: leiomyomas, low malignant leiomyosarcomas, high malignant leiomyosarcomas (P _lt_ 0.01).
Using microdissection and genotyping, we tested 5 leiomyomas, 6 STUMPs, and 10 leiomyosarcomas with follow-up for AI across a panel of seven tumor suppressor genes (p16, p21, p53, VHL, XRCC3, RB, and NM-23).
|Human||MYOG||4656||myogenin (myogenic factor 4)|
No cases of nodular fasciitis, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, inflammatory myofibroblastic tumor, myofibrosarcoma, leiomyoma, leiomyosarcoma, or alveolar soft part sarcoma stained for myogenin.
|Human||GADD45B||4616||growth arrest and DNA-damage-inducible, beta|
In further studies of multiple human cancer tissues, GADD45beta strongly stained tissues such as colon cancer, breast cancer, prostate cancer, squamous cell cancer, lymphoma, and leiomyosarcoma, suggesting that the decreased expression of GADD45beta is specific to HCC.
|Human||MMP2||4313||matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)|
matrix metalloproteinase 2(MMP-2) was uterine smooth muscle tumor of uncertain malignant potential(STUMP), and in 48% of leiomyosarcoma